[Multicenter study of Klimonorm (R) by the Jenapharm firm for treating the climacteric syndrome]

Ginekol Pol. 1995 Apr;66(4):237-45.
[Article in Polish]

Abstract

In our work we evaluated according to Kupperman Index the effectiveness of treating menopausal signs and symptoms during the therapy with estrogen--progestagen preparation Klimonorm firm Jenapharm. During 6 months observation increase in blood pressure was not observed, neither an increase in body weight in a group of 116 women was not observed. Among these, mean Kupperman index was decreased from 28.38 to 11.6 after 3 months and up to 5.47 after 6 months therapy with Klimonorm. These patients estimated this agent as very good and good in 93.21% tolerated as very good and good in 91.43% and 91.59% of these patients planned to continue treatment with Klimonorm.

Publication types

  • Clinical Trial
  • English Abstract
  • Multicenter Study

MeSH terms

  • Climacteric / drug effects*
  • Cloprostenol / pharmacology*
  • Drug Combinations
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Female
  • Humans
  • Levonorgestrel / pharmacology*
  • Middle Aged
  • Patient Satisfaction

Substances

  • Drug Combinations
  • klimonorm
  • Cloprostenol
  • Estradiol
  • Levonorgestrel